133 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
13 May 24
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
of announcements of clinical results, trial initiation, and regulatory filings; outcome of regulatory decisions; potential benefits of luvelta … and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials
8-K
EX-1.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering … as is appropriate to reflect not only the relative benefits referred to in clause (i) of this Section 7(d) but also the relative fault of the Company on the one
424B5
zj2oqottfw25j
2 Apr 24
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
esjtt 0llk
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
ooyozyxnudi5htwog9q
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
EX-99.1
0b9pm8v9izg1 oaj9ffx
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-1.1
m6c xw51klr1y1
9 Feb 24
Other Events
4:27pm
424B5
v44 5kg98k
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
4rdnpo 48zkf
8 Jan 24
Results of Operations and Financial Condition
7:31am